United Capital Financial Advisors LLC Makes New Investment in Immix Biopharma, Inc. $IMMX

United Capital Financial Advisors LLC bought a new position in Immix Biopharma, Inc. (NASDAQ:IMMX) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 70,682 shares of the company’s stock, valued at approximately $729,000. United Capital Financial Advisors LLC owned approximately 0.10% of Immix Biopharma as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also recently made changes to their positions in the company. Bank of America Corp DE purchased a new position in shares of Immix Biopharma in the second quarter worth $4,260,000. Jupiter Topco LLC bought a new stake in shares of Immix Biopharma during the 2nd quarter valued at about $100,816,000. J. Goldman & Co LP bought a new position in shares of Immix Biopharma in the 2nd quarter worth approximately $2,049,000. Legal & General Group Plc purchased a new position in shares of Immix Biopharma in the second quarter worth approximately $41,000. Finally, The Manufacturers Life Insurance Company purchased a new position in shares of Immix Biopharma in the second quarter worth approximately $1,514,000. Hedge funds and other institutional investors own 11.26% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on IMMX. Needham & Company LLC initiated coverage on shares of Immix Biopharma in a research note on Wednesday, July 22nd. They set a “buy” rating and a $21.00 price target on the stock. Bank of America started coverage on Immix Biopharma in a research note on Thursday, June 18th. They issued a “buy” rating and a $27.00 price objective for the company. Morgan Stanley lowered their target price on Immix Biopharma from $20.00 to $19.00 and set an “overweight” rating on the stock in a research report on Tuesday, August 11th. Citigroup reissued a “market outperform” rating on shares of Immix Biopharma in a report on Friday, August 14th. Finally, Lifesci Capital assumed coverage on Immix Biopharma in a research report on Wednesday, June 17th. They issued an “outperform” rating and a $19.00 price target for the company. Eight equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $21.29.

Immix Biopharma Price Performance

Shares of NASDAQ IMMX opened at $13.94 on Monday. The stock has a market cap of $997.25 million, a PE ratio of -15.84 and a beta of 0.11. Immix Biopharma, Inc. has a 1 year low of $1.94 and a 1 year high of $15.10. The firm has a fifty day moving average price of $10.62 and a 200-day moving average price of $9.56.

Immix Biopharma (NASDAQ:IMMX) last released its earnings results on Friday, August 7th. The company reported ($0.18) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.01). On average, research analysts expect that Immix Biopharma, Inc. will post -0.74 EPS for the current year.

About Immix Biopharma

Immix Biopharma (NASDAQ:IMMX) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immuno-oncology therapies that target myeloid checkpoints. The company’s approach centers on harnessing the innate immune system to promote anti-tumor activity, complementing established T-cell checkpoint inhibitors. By modulating key myeloid pathways, Immix Biopharma aims to overcome resistance mechanisms in solid tumors and broaden the scope of effective cancer immunotherapy.

The company’s lead candidate, IMX-110, is a first-in-class combination therapy designed to activate macrophages and dendritic cells within the tumor microenvironment.